SCHEMBL24124191

SCHEMBL24124191

Cc1cc(CNc2ccc3cncnc3c2)ccc1OCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.53
PPARA Q07869 7/20 0.49
MRGPRX1 Q96LB2 3/20 0.47
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
MAPT P10636 3/20 0.46
LMNA P02545 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
EGFR P00533 1/20 0.45
POLB P06746 1/20 0.44
THRB P10828 1/20 0.44
FFAR4 Q5NUL3 1/20 0.44
F2 P00734 1/20 0.44
F10 P00742 1/20 0.44
PRSS1 P07477 1/20 0.44
F7 P08709 1/20 0.44
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25920277 0.87 PPARA (0.45) NOTUMPPARAMRGPRX1KMT2AMEN1
SCHEMBL25920278 0.85 MRGPRX1 (0.43) NOTUMPPARAMRGPRX1KMT2AMEN1
SCHEMBL24124319 0.84 F2 (0.58) NOTUMPPARAMRGPRX1KMT2AMEN1
SCHEMBL24124325 0.84 MEN1 (0.59) NOTUMKMT2AMEN1SMN1; SMN2L3MBTL1
SCHEMBL24124769 0.83 F2 (0.53) NOTUMPPARAMRGPRX1KMT2AMEN1
SCHEMBL24124251 0.83 EGFR (0.54) NOTUMKMT2AMEN1SMN1; SMN2MAPT
SCHEMBL25920276 0.81 PPARA (0.48) NOTUMPPARAKMT2AMEN1L3MBTL1
SCHEMBL25920960 0.79 EGFR (0.48) NOTUMKMT2AMEN1SMN1; SMN2MAPT
SCHEMBL24125166 0.78 NOTUM (0.50) NOTUMKMT2AMEN1SMN1; SMN2L3MBTL1
SCHEMBL24124999 0.78 IMPDH2 (0.50) NOTUMPPARAKMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 US disclosed
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 US disclosed
WO-2021257544-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2021-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA BCL6, SOX18, BCL3 NOTUM 2800/4885PPARA 3017/4885MRGPRX1 2640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.